« Back
The Prestwick Chemical Library (R), A Valuable Tool for Screening
Poster Title: The Prestwick Chemical Library (R), A Valuable Tool for Screening
Submitted on 20 May 2015
Author(s): Jean-Marie Contreras1, Christophe Morice1, Jean-Marc Simon1, Bruno Didier2, Marie-Louise Jung1 and Thierry Langer3
Affiliations: 1. Prestwick Chemical, 220 Blvd Gonthier d'Andernach, 67400 Strasbourg-Illkirch, FRANCE 2. University of Strasbourg, Therapeuthic Innovation Laboratory, UMR7200 CNRS, Faculty of Pharmacy, 74 route du Rhin, 67400 Illkirch, FRANCE 3. University of Vienna, Department of Pharmaceutical Chemistry, Althanstrasse 14, 1090 Vienna, AUSTRIA
This poster was presented at Academic Drug Discovery 2015
Poster Views: 2,359
View poster »

Poster Information
Abstract: The discovery of novel drug molecules is a long, risky, and costly process and constant efforts are undertaken in order to optimize this task. The use of smart and focused chemical libraries has proven its efficiency for hit identification during early drug discovery. The Prestwick Chemical Library ® (PCL) is a product arising from medicinal chemistry expertise comprising currently 1280 off-patent drugs, thus presenting a large degree of chemical and pharmacological diversity within a relatively small number of compounds. The PCL was designed to reduce the risk of "low quality" hits and the cost of the initial screening and may be used for a) assay validation; b) finding hits for a new optimization program; c) repurposing/repositioning; d) finding modulators of stem cell differentiation. Diversity in terms of chemical structure and biological activity will be illustrated and discussed in the poster. Drug repurposing examples and successful screening results will be also reported. The PCL comes in different formats with a fully-annotated database which was recently updated. Numerous publications refer to the PCL for 10+ years.Summary: The Prestwick Chemical Library® (PCL) is Prestwick’s flagship product dedicated to screening. It is a collection of 1280 molecules comprising 100% approved drugs (FDA, EMEA and other agencies) selected for their high chemical and pharmacological diversity. The PCL was designed to reduce the risk of "low quality" hits and therefore the cost of the initial screening, and appears to be an efficient smart library for hit discovery. The PCL comes with an extended fully-annotated database. References: 1. Adv. Drug Delivery Rev. 1997, 23, 3. 2. Curr Opin Chem Biol. 2004 (3):255-63. 3. J. Chem. Inf. Model. 2011, 51, 1762–1774. 4. J. Chem. Inf. Model. 2012, 52, 327−342. 5. 6. Nucleic Acids Research, 2014, Vol. 42, Database issue D1083–D1090. 7. MIMS Drug Information System, Search Drug Information, Interactions, Images, Dosages & Side Effects. 8. WIPO - World Intellectual Property Organization. 9. Vidal. 10. Drug Discov Today. 2014 19(5):637-44. 11. Nature. 2007 Aug 9;448(7154):645-6. 12. Neuromuscular Disorders, 2004, 14, 365-370. 13. Clinical Cancer Research, 2006, 12, 5557-5569. 14. Chemistry & Biology, 2005, 12, 973–980. 15. PNAS 2008, 105 (32), 11218-11223. 16. Plos One 2008, 3 (4), 1981. 17. J Virol. 2009, 83(10), 5148-5155. 18. The Journal of Biological Chemistry 2009 284(14). 9394–9401. 19. Bioorganic & Medicinal Chemistry Letters 2009, 19, 1592–1595. 20. PloS One, 2012, 7, 1-14. 2Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Lutein Esters are more Bioavailable than Free Lutein
Michael Lelah

low-volume workflows improve the quality of drug discovery: two case studies
Margaret Kenney#, Archi Joardar#, Vasudeo Badarinarayana#, Joby Jenkins*

9 popular plant extracts in cosmetics
Tylor Keller

Ionic Liquids
Tylor Keller

Dissecting the genomic profile of persistently infecting oncolytic Newcastle disease virus (NDVpi) from cancer RNA-Seq data
Ahmad U1, Chan SC2, Chau DM1, Chia SL5, Abdullah S1,3, Yusoff K5 & Veerakumarasivam A1,4*